Business Description
China Resources Boya Bio-pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 8260571
Compare
Compare
Traded in other countries / regions
300294.China
Description
China Resources Boya Bio-pharmaceutical Group Co Ltd, formerly Boya Bio-Pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 122.43 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.08 | |||||
Interest Coverage | 58.44 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 17.58 | |||||
Beneish M-Score | -2.92 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.5 | |||||
3-Year EBITDA Growth Rate | -6.3 | |||||
3-Year EPS without NRI Growth Rate | -10.7 | |||||
3-Year Book Growth Rate | 16 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.56 | |||||
9-Day RSI | 53.49 | |||||
14-Day RSI | 52.93 | |||||
6-1 Month Momentum % | -1.12 | |||||
12-1 Month Momentum % | -26.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.45 | |||||
Quick Ratio | 8.34 | |||||
Cash Ratio | 7.09 | |||||
Days Inventory | 206.96 | |||||
Days Sales Outstanding | 63.87 | |||||
Days Payable | 83.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.44 | |||||
Dividend Payout Ratio | 0.09 | |||||
3-Year Dividend Growth Rate | -24.3 | |||||
Forward Dividend Yield % | 0.44 | |||||
5-Year Yield-on-Cost % | 0.37 | |||||
3-Year Average Share Buyback Ratio | -5.7 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 56.51 | |||||
Operating Margin % | 18.19 | |||||
Net Margin % | 12.96 | |||||
ROE % | 6.5 | |||||
ROA % | 5.6 | |||||
ROIC % | 12.91 | |||||
ROC (Joel Greenblatt) % | 26.05 | |||||
ROCE % | 8.24 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 44.93 | |||||
PE Ratio without NRI | 44.93 | |||||
Shiller PE Ratio | 47.44 | |||||
Price-to-Owner-Earnings | 67.49 | |||||
PS Ratio | 5.75 | |||||
PB Ratio | 2.48 | |||||
Price-to-Tangible-Book | 2.87 | |||||
Price-to-Free-Cash-Flow | 13.06 | |||||
Price-to-Operating-Cash-Flow | 12.46 | |||||
EV-to-EBIT | 28.63 | |||||
EV-to-EBITDA | 28.63 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-FCF | 11.26 | |||||
Price-to-Projected-FCF | 2.1 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Graham-Number | 2.39 | |||||
Price-to-Net-Current-Asset-Value | 3.46 | |||||
Price-to-Net-Cash | 4.86 | |||||
Earnings Yield (Greenblatt) % | 3.49 | |||||
Forward Rate of Return (Yacktman) % | -4.1 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 2,681.046 | ||
EPS (TTM) (¥) | 0.76 | ||
Beta | 0.84 | ||
Volatility % | 43.78 | ||
14-Day RSI | 52.93 | ||
14-Day ATR (¥) | 1.091223 | ||
20-Day SMA (¥) | 33.6015 | ||
12-1 Month Momentum % | -26.51 | ||
52-Week Range (¥) | 25.16 - 46.46 | ||
Shares Outstanding (Mil) | 504.25 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
China Resources Boya Bio-pharmaceutical Group Co Ltd Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |